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ABSTRACT
Novel biomarkers are needed to complement prostate specific antigen (PSA) 
in prostate cancer (PCa) diagnostic screening programs. Glycoproteins represent a 
hitherto largely untapped resource with a great potential as specific and sensitive 
tumor biomarkers due to their abundance in bodily fluids and their dynamic and 
cancer-associated glycosylation. However, quantitative glycoproteomics strategies 
to detect potential glycoprotein cancer markers from complex biospecimen are only 
just emerging. Here, we describe a glycoproteomics strategy for deep quantitative 
mapping of N- and O-glycoproteins in urine with a view to investigate the diagnostic 
value of the glycoproteome to discriminate PCa from benign prostatic hyperplasia 
(BPH), two conditions that remain difficult to clinically stratify. Total protein extracts 
were obtained, concentrated and digested from urine of six PCa patients (Gleason 
score 7) and six BPH patients. The resulting peptide mixtures were TMT-labeled and 
mixed prior to a multi-faceted sample processing including hydrophilic interaction 
liquid chromatography (HILIC) and titanium dioxide SPE based enrichment, 
endo-/exoglycosidase treatment and HILIC-HPLC pre-fractionation. The isolated 
N- and O-glycopeptides were detected and quantified using high resolution mass 
spectrometry. We accurately quantified 729 N-glycoproteins spanning 1,310 unique 
N-glycosylation sites and observed 954 and 965 unique intact N- and O-glycopeptides, 
respectively, across the two disease conditions. Importantly, a panel of 56 intact 
N-glycopeptides perfectly discriminated PCa and BPH (ROC: AUC = 1). This study 
has generated a panel of intact glycopeptides that has a potential for PCa detection.
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INTRODUCTION
Prostate cancer (PCa) is the most common non-
cutaneous cancer and the second leading cause of 
cancer-related death in men [1]. Although blood levels 
of prostate specific antigen (PSA) is the most common 
diagnostic marker used for PCa screening, its low 
specificity has raised concerns regarding patient over-
diagnosis and overtreatment [2]. For example, elevated 
serum PSA levels are associated with benign prostatic 
hyperplasia (BPH), a common age-related benign male 
condition, that shares similar clinical symptoms with 
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malignant prostate disorders [3]. The urgent need for novel 
biomarkers that can effectively stratify BPH and PCa 
patients has prompted scientists to search for PCa-specific 
biomolecules in bodily fluids.
Urine is an attractive excreted body fluid for PCa 
biomarker discovery, since it is readily obtained in a non-
invasive manner and may, due to the proximity to the 
prostate, carry biomolecular signatures that reflect the 
aberrant biochemical processes occurring within the prostate 
during PCa development and progression [4, 5]. Mass 
spectrometry-based proteomics has been instrumental in 
the discovery of several candidate biomarkers in urine from 
PCa patients [6]. For example, Ahmad et al. [7] reported 
unusually low urinary levels of fibronectin and TP53INP2 
in PCa patients compared to BPH patients. Jedinak et al. 
[8] reported a panel of differentially expressed proteins in 
PCa compared to BPH urine including β-2-microglobulin 
(β2M), pepsinogen 3 (PGA3), and mucin 3 (MUC3). These 
examples illustrate that sensitive quantitation of aberrant 
protein signatures directly in urine is now technically 
feasible using modern LC-MS/MS technologies. However, 
disappointingly few of the proposed biomarker candidates 
for PCa diagnosis have been validated across multiple 
large PCa patient cohorts and none is, to the best of our 
knowledge, implemented in the clinic for PCa screening. 
Protein glycosylation is increasingly being 
recognized as a modification with a great potential for 
cancer diagnostics [9–15]. Aberrations in the glycosylation 
machinery leading to “tumor-specific” glycan structures or 
epitopes are universal feature of malignant transformation 
and tumor progression [16–18]. Vermassen et al. showed 
that glycan profiling of urinary proteins could discriminate 
PCa from BPH patients [19]. In that specific study, 
N-glycans were released from urinary glycoproteins, 
labeled with with 8-aminopyrene-1,3,6-trisulphonic acid 
and analyzed by a multi-capillary electrophoresis-based 
sequencer. However, no site-specific information of the 
aberrant glycans that showed core fucosylation features 
associated with PCa could be derived from this glycomics 
focused approach. In another study, core fucosylation was 
observed as an enriched glyco-feature in PCa cell lines 
derived from metastatic cells relative to non-tumorigenic 
prostate cells [20]. It remains unclear if such PCa cell lines 
accurately reflect the glyco-phenotype of PCa tissue.
Liu et al. used mass spectrometry to explore former 
N-glycosylated peptides (hereafter de-N-glycosylated 
peptides or de-N-glycopeptides) in normal prostate, non-
aggressive, aggressive and metastatic PCa tissues [21]. In 
total, 1,430 N-glycosylation sites were identified and some 
glycoproteins were proposed as biomarker candidates 
for PCa aggressiveness including N-acylethanolamine 
acid amidase and protein tyrosine kinase 7. Cima et al. 
applied label-free quantitative proteomics to measure 
perturbations in the prostate and serum glycoproteome 
of Pten conditional knockout mice relative to matching 
wildtype mice. In that study, promising candidate 
biomarkers, such as thrombospondin-1 (THBS1), tissue 
inhibitor of metalloproteinase 1 (TIMP-1), complement 
factor H (CFH), and prolow-density lipoprotein receptor-
related protein 1 (LRP-1), were further validated by 
quantitative selected reaction monitoring (SRM) and 
ELISA in the sera of PCa and BPH patients [22]. Shah 
et al. showed altered fucosylation in the androgen-
independent PCa cell line PC3 compared to the androgen-
dependent PCa cell LNCap line using glycoproteomics. 
A total of 1,810 unique N-glycosylation sites from 653 
N-glycoproteins were identified; 176 glycoproteins were 
present in different levels between the two cell lines [20]. 
Core fucosylation was observed as an enriched glyco-
feature in PCa cell lines derived from metastatic cells 
relative to non-tumorigenic prostate cells [20]. However, 
it remains unclear if such PCa cell lines accurately reflect 
the glyco-phenotype of PCa tissue.
Collectively, these studies have demonstrated the 
immense potential of present day mass spectrometry to 
map the glycoproteome and identify glycoproteins with 
untapped diagnostic potential to report on malignant 
transformation. However, to the best of our knowledge, 
no studies have to date profiled site-specific protein 
glycosylation features directly in urine from PCa and 
relevant control donors to investigate the potential of using 
aberrant glycoproteome signatures as accurate molecular 
reporters of PCa development and progression.
Despite of the impressive progress achieved in 
the now streamlined genome and proteome sequencing 
methods over the past decades, glycoproteomics 
technologies remain under-developed and are still only 
utilized in specialist laboratories [23, 24]. Technical 
challenges are still preventing or at least discouraging 
more general Proteomics focused laboratories. Key steps 
in the glycoproteomics workflow including glycopeptide 
enrichment, liquid chromatography–mass spectrometry 
(LC-MS/MS) acquisition and computational data analysis 
are still common bottlenecks that limit the identification 
rate and the quantitative accuracy when investigating 
the extensive micro- and macro-heterogeneity inherently 
associated with the N- and O-glycoproteome [25, 26].
We recently described a method for site-specific 
characterization of the N-glycan composition, peptide 
carrier and glycosylation sites from urinary glycoproteins 
and endogenous glycopeptides of healthy donors [27]. 
Hydrophilic interaction liquid chromatography (HILIC) 
SPE-enriched glycopeptides were analyzed in their intact 
form by LC-MS/MS; in total, 472 unique N-glycosylation 
sites and 303 intact N-glycopeptides from 256 urinary 
N-glycoproteins were identified. Following on our 
previous work in urinary glycoproteomics, we here set 
out to expand our coverage of the urinary glycoproteome 
by combining complementary glycopeptide enrichment 
and pre-fractionation strategies with exo- and endo-
glycosidase digestion prior to LC-MS/MS. Importantly, 
we use isobaric labels to facilitate accurate quantitative 
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glycoproteomics between and within donor groups to more 
effectively investigate the potential of intact glycopeptides 
as signatures for PCa detection and precise stratification 
from BPH conditions.
The innovative aspects of this study are summarized 
as follows: 1) we present a mass spectrometry-based 
method for a highly sensitive site-specific and quantitative 
characterization of the N- and O-glycosylation decorating 
urinary proteins, 2) we used this method to obtain the largest 
map of human urinary glycoproteome to date including 
identifying glycosylated proteins, glycosylation sites and 
site-specific glycan compositions, and importantly 3) 
this method also showed that a panel of PCa-associated 
glycoproteins, as measured by intact glycopeptides, can be 
used to discriminate urine from PCa and BPH. Technical 
aspects pertaining to this glycoproteomics strategy and the 
panel of PCa-associated urinary glycoproteins are here 
discussed in the context of PCa detection and prostate 
biology. 
RESULTS 
Quantitative glycoproteomics enable exploration 
of the urinary N- and O-glycoproteome
Urine samples (~2 ml) from six PCa and six BPH 
patients were obtained and investigated in this study. 
The PCa group included only patients with clinically 
validated adenocarcinoma with Gleason score 7 (GS 7), 
which denotes intermediate grade PCa relative to GS 
6 representing low-risk PCa suitable for an active 
surveillance program, and the more advanced GS 8–10 
representing high-risk PCa cases that generally are 
referred to immediate treatment. The serum PSA levels of 
the PCa patient group were 7.17 ± 3.02 ng/ml (n = 6) and 
8.02 ± 7.30 ng/ml in the BPH patient group (n = 6). 
As expected, no significant difference was observed in 
the serum PSA levels between these two patient groups 
(p ≥ 0.05, n = 6, unpaired two-tailed t-test, Figure 1A) 
highlighting the shortcoming of this biomarker to 
accurately stratify PCa and BHP patients. Lower yields 
of total urinary protein were observed from two biological 
replicates from both the PCa and BPH groups; hence, these 
protein-poor samples were combined (1:1, w/w) forming 
five biological replicates (n = 5) from each condition for 
comparative glycoproteomics.
Given the reasonably large protein starting 
material (~100 µg/replicate), we applied a multi-faceted 
quantitative LC-MS/MS-based glycoproteomics strategy 
to obtain a deep coverage of the urinary glycoproteome 
and investigate for differentially abundant glycoproteins 
in PCa and BPH urine. In short, after protein extraction, 
concentration and tryptic digestion of the 10 samples, the 
resulting peptide mixtures were labeled with an isobaric 
amine-reactive TMT10plex – peptides from the five PCa 
samples were labeled with TMT 126, 127N, 127C, 128N 
and 128C and peptides from the five BPH samples were 
labeled with TMT 129N, 129C, 130N, 130C and 131. All 
TMT-labelled peptide samples were then mixed in 1:1 
(w/w) relationships prior to a multi-faceted glycopeptide 
enrichment and pre-fractionation sample processing 
(Figure 1B).
The glycopeptide enrichment was performed 
using two complementary solid phase extraction (SPE) 
strategies i.e. titanium dioxide (TiO2) SPE and HILIC SPE 
enrichment, to reach the deepest possible coverage of the 
urinary glycoproteome. The sialic acid-retaining TiO2 SPE 
[28, 29] was included since we previously showed that 
urinary N-glycoproteins are highly sialylated [27]. HILIC 
SPE is widely recognized to capture all glycopeptides 
displaying a minimum degree of hydrophilicity regardless 
of the nature of their conjugated glycan structure 
[30, 31]; however, this enrichment method may come 
short of quantitatively capturing O- and N-glycopeptides 
of very low hydrophilicity (unpublished observation). 
The TiO2 and HILIC SPE enriched glycopeptides were 1) 
analyzed directly in their intact form by high resolution 
LC-MS/MS on a Orbitrap Q-Exactive HF with HCD 
fragmentation, which provided information of the peptide 
carrier and site-specific glycan heterogeneity, or 2) treated 
simultaneously with N-glycosidase F (PNGase F) and 
sialidase A to generate de-N-glycosylated and desialo-
O-glycopeptides that are less challenging to characterize 
by LC-MS/MS. Combining the latter approach with a 
similar Orbitrap Q-Exactive HF HCD based acquisition, 
provided N-glycosylation site information and site-specific 
glycan information of the O-glycosylation. In addition, 
non-modified peptides that did not bind to the TiO2 SPE 
column (“flow through”) and PNGase F/sialidase-treated 
glycopeptides were pre-fractionated using off-line HILIC 
HPLC and the resulting fractions were analyzed by 
Orbitrap Q-Exactive HF HCD-MS/MS (Figure 1B).
Complementary TiO2 and HILIC SPE-based 
glycopeptide enrichment provide deep coverage 
of the urinary glycoproteome
Even without peptide pre-fractionation, the 
combined use of TiO2 and HILIC SPE facilitated the 
identification of 630 unique N-linked glycosylation sites 
belonging to 361 N-glycoproteins across the urine samples 
(Supplementary Figure 1A, and Supplementary Tables 
1–2). Partial overlap between the TiO2 and HILIC SPE 
enrichment approaches were observed when measured 
by the proportion of unique N-glycosylation sites (48%, 
304/630) and the corresponding glycoproteins (58%, 
211/361) detected in both sample preparation techniques 
(Supplementary Figure 1B–1C). However, when assessed 
by the identified intact glycopeptides, the enrichment 
strategies displayed high complementarity: From a 
combined total of 954 N- and 210 O-glycopeptides 
identified with high peptide confidence (0% peptide 
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FDR Pep-2D) [32] (Supplementary Figure 1D and 
Supplementary Tables 3–6), the degree of unique N- and 
O-glycopeptides identified from both the TiO2 and HILIC 
SPE preparations was 23% (216/954) and 10% (20/210), 
respectively (Supplementary Figure 1E–1F).
Due to the unbiased enrichment of the hydrophilic 
glycopeptides, HILIC SPE showed, as expected, a higher 
capture efficiency of N-glycopeptides compared to TiO2 
SPE. In contrast, TiO2 retained a greater number of 
O-glycopeptides compared to HILIC SPE indicating a 
high degree of sialylation of the O-glycopeptides and an 
inability of HILIC SPE to retain such lowly hydrophilic 
glycopeptides. 
We also investigated the glycosylation features of 
the TiO2 and HILIC SPE enriched intact N-glycopeptides 
(Supplementary Figure 1G, Supplementary Tables 
3–4) and O-glycopeptides (Supplementary Figure 1H, 
Supplementary Tables 5–6). In agreement with our previous 
study [27], the urinary N-glycoproteins were predominantly 
carrying complex and hybrid type N-glycans with a high 
level of fucosylation and/or sialylation accounting for ~85% 
of all identified intact N-glycopeptides (Supplementary 
Figure 1G). Sialylated O-glycopeptides were also abundant 
(~70%) and were, as expected, efficiently enriched using 
TiO2 SPE (Supplementary Figure 1H). Collectively, these 
data clearly demonstrated that the parallel usage of HILIC 
Figure 1: TMT label-assisted quantitative glycoproteomics of urinary glycoprotein from PCa and BPH patients. (A) 
The serum PSA levels of PCa (n = 6) and BPH (n = 6) patients showed no statistical difference (p > 0.05, unpaired two tailed t-test). (B) 
Overview of the quantitative glycoproteomics workflow employed in this study. Peptides were generated from extracted urinary proteins 
from each patient, labelled with isobaric TMT tags and mixed 1:1 (w:w). The glycopeptides were selectively enriched using either TiO2 
or HILIC SPE and the resulting fractions were either analyzed directly or after simultaneous endo- and exoglycosidase treatment by LC-
MS/MS. Former N-glycosylated peptides generated by PNGase F (referred to as de-N-glycosylated peptides) and desialo-O-glycosylated 
peptides generated by sialidase and non-modified peptides were pre-fractionated using off-line HILIC HPLC; the resulting fractions were 
analyzed by LC-MS/MS. Different information was obtained from the analysis of intact glycopeptides (red), de-N-glycopeptides (green) 
and non-modified peptides (blue). 
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and TiO2 SPE is highly beneficial to increase the coverage 
of the urinary N- and O-glycoproteome.
HILIC HPLC pre-fractionation enhances the 
coverage of the urinary glycoproteome
In attempts to reach an even greater coverage of 
the urinary glycoproteome, off-line HILIC HPLC was 
implemented in the workflow to pre-fractionate the TiO2 
SPE retained glycopeptide fraction. Endo- (PNGase F) and 
exo- (broad specificity sialidase) glycosidase treatments 
were also introduced to render the HILIC peptide 
fractions more amendable to LC-MS/MS detection; it 
is commonly known that such de-N-glycosylated and 
desialo-O-glycopeptides are easier to identify than 
their native counterparts, albeit with less structural 
information obtained [33, 34]. Interesting, the de-N-
glycosylated peptides eluted early in the HILIC HPLC 
gradient and were efficiently separated from the highly 
retained desialo-O-glycopeptides (Figure 2A). When 
combined with Orbitrap Q-Exactive HF HCD-MS/MS 
detection, the HILIC HPLC pre-fractionation facilitated 
an unprecedented coverage of the urinary glycoproteome 
by the identification of a total of 1,217 N-glycosylation 
sites from 696 N-glycoproteins and the detection of 
887 desialo-O-glycopeptides from 160 O-glycoproteins 
(Figure 2B and 2C and Supplementary Tables 7–8).
In total, 1,310 N-glycosylation sites were identified 
by combining the de-N-glycosylated peptides enriched by 
HILIC SPE and TiO2 SPE and pre-fractionated by HILIC 
HPLC (Supplementary Tables 2, 7). We then compared 
our coverage of the urinary N-glycosylation sites in PCa 
and BPH urine to a SWATH based identification of the 
N-glycosylation sites reported in normal prostate, non-
aggressive, aggressive and metastatic PCa tumor tissues 
[21]; a substantial overlap of 337 unique glycosylation 
sites (25%) and 321 N-gycoproteins (44%) was observed 
(Supplementary Figure 2A–2B). This result indicates 
that almost half of the glycoproteins expressed in 
prostate tissues appear to be mirrored in the excreted 
urine. We then compared our urinary N-glycoproteome 
coverage to the N-glycoproteome of two PCa cell lines 
LNCap and PC3 reported by Shah et al. [20]. In total, 
134 N-glycoproteins (11%) were found to be common 
between our two data sets (Supplementary Figure 2B). 
Interestingly, the urinary glycoproteins identified in our 
study had a closer resemblance to the glycoproteome of 
PCa tissues than the glycoproteome of the PCa cell lines. 
Quantitative comparison of PCa-associated 
glycan-compositions and lectin blotting analysis
We compared the relative abundance of all intact 
N-glycopeptides grouped by glycan class and terminal 
features from PCa and BPH urine. In doing this, no 
significant differences were observed between PCa and 
BPH with respect to the overall relative abundance of 
high mannose, afucosylated/asialylated complex/hybrid 
(C/H), fucosylated complex/hybrid (C/H+Fuc), sialylated 
complex/hybrid (C/H+NeuAc), and fucosylated/sialylated 
complex/hybrid (C/H+Fuc/Sia). However, increased 
intensity of Fuc-containing intact desialo-O-glycopeptides 
was observed (T-test, p < 0.05) (Supplementary Figure 3).
Comparative lectin blotting was also performed 
using concanavalin A (Con A), Maackia amurensis 
lectin (MAL), wheat germ agglutinin (WGA), Aleuria 
aurantia lectin (AAL) and Ricinus communis agglutinin 
(RCA) to assess the level of a range of glycoepitopes 
in PCa and BPH urine in an orthogonal manner. After 
protein normalization, significantly increased levels 
of AAL reactivity were observed for the PCa urinary 
glycoproteome indicating a higher degree of core 
fucosylation (Figure 3). Slightly higher Con A reactivity 
was also observed in PCa relative to BPH urine, a feature 
not reflected in the quantitative LC-MS/MS data of high 
mannose glycopeptides. However, Con A may also cross-
react with paucimannosidic and biantennary complex 
glycoproteins possibly explaining this discrepancy [35]. 
Based on these observations, we therefore sought to 
determine whether site-specific glycosylation instead 
would display a higher potential of discriminating between 
urine from PCa and BPH patients. 
Comparative quantitative glycoproteomics 
to identify unique site-specific glycosylation 
signatures in PCa urine
The datasets of de-N-glycosylated peptides and 
desialo-O-glycopeptides generated after TiO2 SPE-
based glycopeptide enrichment and HILIC HPLC pre-
fractionation as well as the intact N-glycopeptides 
identified after HILIC SPE and TIO2 SPE-based 
glycopeptide enrichments was used to quantitatively 
compare the glycosylation profile of PCa and BPH urine 
using TMT reporter ion intensities. In addition, to assess 
for altered protein levels, the intensities from the non-
modified peptides (TiO2 SPE flow-through fraction) were 
also compared between PCa and BPH. The ion intensities 
of all glycopeptides or non-modified peptides were 
summed, log2 transformed, and median normalization 
was applied. One BPH sample showed different outlier 
behavior when comparing all samples using PCA and 
was therefore removed. To reveal statistical differences 
in the abundance of glycopeptides from PCa (n = 5) and 
BPH groups (n = 4), the Limma R package was used 
[36]. The total number of differentially abundant intact 
N-glycopeptides and desialo-O-glycopeptides, de-N-
glycosylated peptides and non-modified peptides, are 
shown in Figure 2D and Supplementary Table 9.
We then performed unsupervised PCA to assess 
if these glycopeptides and non-modified peptides were 
able to discriminate PCa from BPH. Excitingly, all 
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differentially abundant peptides, including the intact N- 
and O-glycopeptides, de-N-glycosylated peptides and non-
modified peptides, were able to almost completely separate 
the PCa and BPH groups (Supplementary Figure 4A). 
Using only the non-modified peptides that were 
significantly changing in abundance, an overlap between 
PCa and BPH groups was observed. Interestingly, only 
the differentially abundant intact N-glycopeptides and 
desialo-O-glycopeptides separated completely the PCa 
and BPH groups in the PCA. As a complementary data 
representation style, we performed clustering analysis 
using Euclidean distance and a heat map to visualize the 
altered levels of intact N-glycopeptides and desialo-O-
glycopeptides. Two large clusters of glycopeptides were 
observed containing 120 over-represented glycopeptides 
and 106 under-represented glycopeptides in PCa 
compared to BPH (Supplementary Figure 4B). These 
clusters perfectly separated the PCa samples from the 
BPH samples. These results showed that the urinary 
glycoproteome provided better discrimination between 
the PCa and BPH groups than the non-modified peptides. 
Parallel reaction monitoring (PRM), a targeted 
proteomics strategy [37], was performed to: 1) confirm 
the levels of some intact glycopeptides in PCa urine; 2) 
increase the number of peptide-spectrum matches (PSM) 
for the individual intact glycopeptides to improve the 
identification confidence and 3) improve the quantification 
accuracy and ion statistics of intact glycopeptides with 
aberrant levels in the PCa urinary glycoproteome. 
The intact N-glycopeptide SVVAPATDG 
GLNLTSTFLR displaying the triantennary and core-
fucosylated sialoglycoform HexNAc(5)Hex(6)Fuc(1)
NeuAc(3) from prostaglandin-H2 D-isomerase (PTGDS) 
was present in 29 PRM-MS/MS spectra within the 
retention time 31.2–32.9 min. The intact O-glycopeptide 
DLCNFNEQLENGGTSLSEK carrying the glycoform 
HexNAc(3)Hex(1)Fuc(1) from CD59 glycoprotein 
(CD59) was present in 24 PRM-MS/MS spectra within 
Figure 2: Deep coverage of the urinary N- and O-glycoproteome using HILIC HPLC pre-fractionation reveals 
quantitative glycoproteome differences in PCa and BPH. (A) Distribution of de-N-glycopeptides and intact desialo-O-
glycopeptides identified across the fractions arising from the HILIC HPLC pre-fractionation of TiO2 SPE enriched peptides of urinary 
proteins. (B) Total and unique de-N-glycopeptides/N-glycoproteins and (C) intact desialo-O-glycopeptides/O-glycoproteins after HILIC 
HPLC pre-fractionation. (D) Overview of the differentially abundant intact N-glycopeptides (from TiO2 and HILIC SPE enrichment), 
desialo-O-glycopeptides, de-N-glycosylated peptides and non-modified peptides identified in the glycoproteome of PCa relative to BHP 
urine.
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the retention time 22.8–24.9 min. In comparison, each of 
these two glycopeptides were only identified from two 
acquired MS/MS spectra in a data-dependent acquisition 
(DDA) mode (Supplementary Tables 4 and 6). The TMT 
reporter ion intensities from the identified spectra of each 
glycopeptide were summed and normalized to the sum of 
all TMT reporter ion intensities from each TMT10plex 
channel during the entire LC-MS/MS run. Statistical 
differences were assessed by conventional t-test analyses. 
The increased levels of the HexNAc(5)Hex(6)Fuc(1)
NeuAc(3) N-glycopeptide from PTGDS and decreased 
levels of the HexNAc(3)Hex(1)Fuc(1) O-glycopeptide 
Figure 3: Lectin blotting analysis of PCa and BPH urine. Proteins from PCa and BPH urine (20 ug) were separated on SDS-
PAGE gels, transferred to PVDF membranes and blotted against Con A (A), MALII (B), WGA (C), RCA (D), AAL (E) lectins. The 
intensity of each lane after lectin blotting was normalized by the intensity of the respective sample stained by Coomassie (F).
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from CD59 in PCa compared to BPH urine was confirmed 
(Supplementary Figure 5). Example of annotated PRM-
MS/MS spectra of these two intact N- and O-glycopeptides 
are shown in Supplementary Figure 6. Importantly, 
seven non-modified peptides from CD59 and eight 
non-modified peptides from PTGDS were identified. 
Most of these non-modified peptides were unaltered in 
abundance when comparing between the PCa and BPH 
urine (Supplementary Table 10). This indicates that the 
expression levels of these two glycoproteins are likely not 
altered in PCa, but that the glycosylation of them instead 
is the molecular feature undergoing regulation. 
Intact N-glycopeptide marker panel for PCa 
diagnosis
To provide a panel of confidently characterized 
PCa-associated intact glycopeptides, we selected only 
intact N-glycopeptides with significant changes in 
abundance, whose glycosylation sites were also identified 
in the de-N-glycosylated peptide fractions and whose 
glycan compositions were commonly known human 
serum glycoforms reported in UniCarbKB [38]. Besides, 
we considered only intact glycopeptides displaying fold 
changes greater than 1.3 or less than 0.77 when comparing 
PCa to BPH urine. A total of 56 intact N-glycopeptides 
matched these criteria (Table 1). Information of the 
relative levels of their corresponding glycoproteins was 
obtained using quantitative LC-MS/MS data of the non-
modified peptide fraction (Supplementary Table 10).
Table 1 shows site-specific glycoforms that are 
more/less abundant in PCa independently of the protein 
level. For example, protein AMBP (AMBP) was clearly 
more abundant at the protein level (as detected by ten non-
modified peptides with increased levels, Supplementary 
Table 9) and site-specific glycan regulation was observed 
by the increased relative abundance of three intact 
glycopeptides covering two N-glycosylation sites in 
PCa urine (Table 1). On the other hand, apolipoprotein 
D (APOD) was less abundant in PCa (two non-modified 
peptides with decreased levels, Supplementary Table 9), 
but increased levels of site-specific glycosylation (i.e. 
HexNAc(7)Hex(6)) were observed. In contrast, LTF was 
found to be both less abundant at the protein level (six 
under-represented non-modified peptides in PCa) and with 
respect to the N-glycosylation site occupancy as evaluated 
by the under-representation of the de-N-glycosylated 
peptide TAGWNIPMGLLFDQTGSCK and the site-
specific hybrid glycoform HexNAc(4)Hex(7)NeuAc(1) in 
PCa. Most of the glycoproteins showed no changes at the 
protein level, but were aberrantly changing with respect 
to their site-specific glycosylation levels e.g. CLU, LOX, 
SERPINA4, WFDC2, LAIR1, PIK3IP1 (Table 1). This 
indicates that the glycosylation machinery, and not the 
protein translation and secretion, of the cells producing 
these cancer-associated glycoforms is significantly 
impacted by the malignant processes associated with PCa.
Some glycopeptides of the urinary glycoproteome 
were putatively identified with terminal NeuGc. 
Although being a non-human type of sialic acid, NeuGc 
may, however, be a component of human glycoproteins 
arising from exogenous building blocks in particular in 
glycoproteins of cancer cell origin [39]. These putative 
NeuGc-containing glycopeptides were manually checked 
for the presence of the corresponding oxonium ions i.e. 
m/z 308/290 in the corresponding HCD-MS/MS spectra. 
All of the glycopeptides showed diagnostic ions for NeuAc 
(m/z 274/290) instead of NeuGc. The molecular mass of 
the compositions HexNAc(5)Hex(6)Fuc(1)NeuAc(2)
NeuGc(1), HexNAc(5)Hex(6)Fuc(1)NeuAc(1)NeuGc(1), 
HexNAc(5)Hex(6)Fuc(1)NeuAc(2)NeuGc(1), HexNAc(4)
Hex(5)Fuc(1)NeuAc(1)NeuGc(1) are identical to the 
mass of HexNAc(5)Hex(7)NeuAc(3), HexNAc(5)Hex(7)
NeuAc(2), HexNAc(5)Hex(7)NeuAc(3), HexNAc(4)
Hex(6)NeuAc(2), respectively. As verified by manual 
annotation, the NeuAc-containing glycoforms were found 
to be the correct glycan composition in all of these cases, 
Table 1. Besides, the composition HexNAc(4)Hex(5)
NeuGc(1) was found to be incorrectly identified due to an 
concomitant oxidation of the peptide. In fact, the correct 
composition was HexNAc(4)Hex(5)NeuAc(1). 
PCA was performed using a panel of 56 intact 
N-glycopeptides identified with high confidence. Complete 
segregation was observed between PCa and BPH 
(Figure 4A). Interestingly, both the abundance of the 
glycosylation sites (as measured by the de-N-glycosylated 
peptides) and proteins (measured by the non-modified 
peptides) from the glycoproteins that were present at 
different levels in PCa vs BHP were not able to discriminate 
between the two diseases (Figure 4B–4C). These results 
indicate that most PCa-specific glyco-features are not due to 
quantitative changes in the protein or site occupancy level, 
but arise from altered abundance of specific glycoforms of 
the individual urinary glycoproteins from the PCa patients.
The PCa-specific panel of 56 intact N-glycopeptide 
was also visualized by a heat map. Unsupervised 
clustering was able to accurately separate the PCa and 
BPH donors groups (Figure 4D). 
The N-glycopeptide panel was also evaluated 
by ROC curve analysis. The AUC was calculated 
using combinations of 3, 5, 10, 20, 28 and 56 selected 
N-glycopeptides within the entire glycopeptide 
panel (56 N-glycopeptides). Using 20, 28 or 56 
intact N-glycopeptides, an AUC of 1 was obtained 
demonstrating high specificity and sensitivity of these 
urinary glycopeptides in the discrimination between the 
PCa patients from the BHP patients (Figure 4E).
The relationship between the glycoproteins that carried 
aberrant N-glycosylation in PCa relative to BHP was explored 
in a protein-protein network analysis to search for over-
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Table 1: Differentially abundant intact N-glycopeptides identified in PCa and BPH urine (PCa = 5, BPH = 4, limma 
test, q < 0.25)
Protein ID Intact N-glycopeptides de-N-gycosylated glycosylated peptides Non-modified peptides
UniProtKB 
ID Gene Protein
N-glycan composition
q-value
Ratio* 
PCa/
BPH
Direction N-Glycosylation site (de)
Ratio* 
PCa/
BPH
# 
peptides
Av. 
ratio* 
PCa/
BPHHexNAc Hex Fuc NeuAc
P01042 KNG1 Kininogen-1 6 7 1 4 0.22 0.47 Down PCa LNAENN(de)ATFYFK 1.10 20 1.7
P01857 IGHG1
Immunoglobulin 
heavy constant 
gamma 1
4 5 1 1 0.20 2.18 Up PCa EEQYN(de)STYR 1.15 10 0.8
P01859 IGHG2
Immunoglobulin 
heavy constant 
gamma 2
4 4 1 0.20 0.49 Down PCa EEQFN(de)STFR 0.74 3 0.5
P01877 IGHA2
Immunoglobulin 
heavy constant 
alpha 2
5 3 1 0.20 1.58 Up PCa TPLTAN(de)ITK 0.68 2 1.3
P02760 AMBP Protein AMBP
4 5 1 0.23 1.60 Up PCa YFYN(de)GTSMACETF
QYGGCMGNGNNFVTEK
1.90
24 2.45 6 0.23 2.47 Up PCa YFYN(de)GTSMACETF
QYGGCMGNGNNFVTEK
1.90
6 6 1 0.20 3.32 Up PCa YFYN(de)GTSMACETF
QYGGCMGNGNNFVTEK
1.90
P02765 AHSG Alpha-2-HS-glycoprotein
4 5 2 0.20 0.33 Down PCa
AALAAFNAQNN(de)
GSNFQLEEISR
1.38
8 1.7
4 6 1 0.20 2.56 Up PCa AALAAFNAQNN(de)
GSNFQLEEISR
1.38
P02788 LTF Lactotransferrin 4 7 1 0.23 0.51 Down PCa
TAGWNIPMGLLFN
(de)QTGSCK
0.52 23 0.7
P05090 APOD Apolipoprotein D 7 6 0.24 1.40 Up PCa ADGTVNQIEGEATPVN(de)LTEPAK 2.78 6 0.6
P05155 SERPING1 Plasma protease C1 inhibitor 4 5 2 0.20 2.76 Up PCa
ASSNPN(de)
ATSSSSQDPESLQDR 0.92 5 1.5
P07911 UMOD Uromodulin
5 7 3 0.20 0.35 Down PCa
FALLMTNCYATPSSN
(de)ATDPLK 0.87
29 1.4
4 6 1 0.20 0.14 Down PCa
FALLMTNCYATPSSN
(de)ATDPLK 0.87
5 4 1 0.20 0.30 Down PCa
FALLMTNCYATPSSN
(de)ATDPLK 0.87
6 7 3 0.23 0.46 Down PCa
FALLMTNCYATPSSN
(de)ATDPLK 0.87
6 7 2 0.25 0.54 Down PCa
FALLMTNCYATPSSN
(de)ATDPLK 0.87
6 5 1 3 0.20 0.58 Down PCa
FALLMTNCYATPSSN
(de)ATDPLK 0.87
9 4 1 0.20 0.76 Down PCa
FALLMTNCYATPSSN
de)ATDPLK 0.87
7 6 0.20 1.55 Up PCa FALLMTNCYATPSSN(de)ATDPLK 0.87
5 6 2 0.23 0.59 Down PCa
CNTAAPMWLN
(de)GTHPSSDEGIVSR
1.03
5 6 1 3 0.20 0.19 Down PCa
QDFN(de)
ITDISLLEHR 1.16
6 7 4 0.20 0.48 Down PCa
QDFN(de)
ITDISLLEHR 1.16
P08185 SERPINA6 Corticosteroid-binding globulin 4 5 2 0.20 0.32
Down 
PCa
AQLLQGLGFN(de)
LTER 0.67
P10909 CLU Clusterin
4 5 2 1 0.23 1.61 Up PCa LAN(de)
LTQGEDQYYLR
0.80
6 1.65 6 3 0.20 3.01 Up PCa KEDALN(de)ETR 1.46
4 5 2 0.23 2.46 Up PCa EDALN(de)ETR 1.56
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represented biological functions and pathways. Significant 
enrichment of pathways pertaining to the complement and 
coagulation cascade (KEGG pathway) and a regulation of 
immune system response (Gene Ontology Biological process) 
were observed in the network of glycoproteins carrying 
aberrant glycosylation in PCa (Figure 4F).
CD59 CD59 glycoprotein
2 2 0.23 1.48 Up PCa TAVN(de)CSSDFDACLITK 1.18
7 2.1
5 5 1 1 0.22 1.54 Up PCa TAVN(de)CSSDFDACLITK 1.18
4 5 2 0.21 1.67 Up PCa TAVN(de)CSSDFDACLITK 1.18
5 5 1 0.22 1.70 Up PCa TAVN(de)CSSDFDACLITK 1.18
P13987 4 6 1 1 0.23 1.71 Up PCa TAVN(de)CSSDFDACLITK 1.18
5 5 1 1 0.25 1.73 Up PCa TAVN(de)CSSDFDACLITK 1.18
5 5 1 0.24 1.73 Up PCa TAVN(de)CSSDFDACLITK 1.18
4 6 1 1 0.24 1.78 Up PCa TAVN(de)CSSDFDACLITK 1.18
4 6 2 0.24 1.91 Up PCa TAVN(de)CSSDFDACLITK 1.18
P28300 LOX Protein-lysine 6-oxidase
4 5 1 2 0.20 2.43 Up PCa DPGAAVPGAAN(de)ASAQQPR 1.21
1 1.94 6 2 0.20 2.82 Up PCa DPGAAVPGAAN(de)ASAQQPR 1.21
4 5 1 1 0.23 1.84 Up PCa RDPGAAVPGAAN(de)ASAQQPR 1.54
P29622 SERPINA4 Kallistatin
4 5 1 0.21 0.34 Down PCa FLN(de)DTMAVYEAK 0.85
4 5 2 0.21 0.34 Down PCa FLN(de)DTMAVYEAK 0.85
P41222 PTGDS Prostaglandin-H2 D-isomerase
5 7 2 0.25 0.45 Down PCa WFSAGLASN(de)SSWLR 0.34
8 2
4 5 1 2 0.20 0.32 Down PCa WFSAGLASN(de)SSWLR 0.34
5 6 2 0.20 0.63 Down PCa WFSAGLASN(de)SSWLR 0.34
5 6 1 3 0.21 0.47 Down PCa
SVVAPATDGGLN(de)
LTSTFLR 0.93
6 7 1 2 0.20 0.48 Down PCa
SVVAPATDGGLN(de)
LTSTFLR 0.93
5 7 1 1 0.22 0.64 Down PCa
SVVAPATDGGLN(de)
LTSTFLR 0.93
P41271 NBL1
Neuroblastoma 
suppressor of 
tumorigenicity 1
4 5 1 2 0.22 1.76 Up PCa N(de)ITQIVGHSGCEAK 1.24 1 3.6
Q07954 LRP1
Prolow-density 
lipoprotein 
receptor-related 
protein 1
2 2 1 0.24 1.97 Up PCa QSGDVTCN(de)CTDGR 1.65 2 1.9
Q14508 WFDC2
WAP four-
disulfide core 
domain protein 2
5 7 3 0.20 1.95 Up PCa TGVCPELQADQN(de)CTQECVSDSECADNLK 1.30
6 1.64 6 1 0.22 1.90 Up PCa TGVCPELQADQN(de)CTQECVSDSECADNLK 1.30
6 3 1 2 0.20 2.12 Up PCa TGVCPELQADQN(de)CTQECVSDSECADNLK 1.30
Q6GTX8 LAIR1
Leukocyte-
associated 
immunoglobulin-
like receptor 1
5 6 1 1 0.24 2.10 Up PCa STYN(de)DTEDVSQASPSESEAR 0.96
2 1.8
4 5 1 1 0.21 2.16 Up PCa STYN(de)DTEDVSQASPSESEAR 0.96
Q96FE7 PIK3IP1
Phosphoinositide-
3-kinase-
interacting 
protein 1
4 6 2 0.23 0.65 Down PCa
CLNWLDAQSGLASAPVS
GAGN(de)HSYCR
0.57
6 1.7
5 6 1 3 0.25 0.63 Down PCa
CLNWLDAQSGLASAPV
SGAGN(de)HSYCR
0.57
Only intact N-glycopeptides detected with significant differences in abundance (ratio PCa/BPH >1.3 and <0.76), carrying a glycan composition reported in UniCarbKB and with the glycosylation site 
confirmed in the de-N-glycosylated peptide fraction are displayed in this table.
*Ratio was calculated by the average of normalized TMT reporter intensities from the PCa (n = 5) and BPH (n = 4) samples.
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In support of our finding, many of the glycoproteins 
in our panel were already shown in previous studies 
to be altered in PCa or involved in tumor growth and 
development. For example: AMBP for PCa diagnosis [40], 
CD59 associated with PCa progression [41–43], CLU as 
a therapeutic target against PCa [44] and predictor for 
PCA recurrence [45], and PTGDS was found in increased 
concentration in urine from PCa patients [40]. The 
association of these glycoproteins to PCa in these previous 
studies was established based on the protein expression 
level. In contrast, we show here for the first time, that site-
specific glycan compositions are also altered in this set of 
glycoproteins in PCa. 
DISCUSSION
In this study, 1,310 de-N-glycosylated peptides, 
954 intact N-glycopeptides and 887 desialylated but 
otherwise intact O-glycopeptides belonging to a total of 
788 glycoproteins were identified. This deep coverage 
should be evaluated in the light of past efforts in this space 
including a study by Halim et al. [46], which showed the 
characterization of 58 N- and 63 O-glycopeptides from 53 
urinary glycoproteins, Saraswat et al. [47] who reported 
51 N-glycosylation sites belonging to 37 glycoproteins 
from the urinary exosomes and our own past study 
of urine i.e. Kawahara et al. [27] reporting 472 unique 
Figure 4: Intact N-glycopeptides as candidate biomarkers for PCa detection. (A) Principal component analysis (PCA) using a 
panel of 56 N-glycopeptides with aberrant levels in PCa relative to BHP (Table 1). (B) PCA using a set of 27 deamidated peptides covering 
the same glycosylation sites as identified with intact N-glycopeptide analysis (Table 1). (C) PCA using a set of non-modified peptides from 
the glycoproteins that carried the panel of differentially abundant intact N-glycopeptides (Table 1). (D) Clustering of intact N-glycopeptides 
displaying altered expression in PCa is shown as a heat map after applying Euclidean distance. (E) ROC curve analysis was performed 
based on partial least squares discriminant analysis (PLS-DA) using the panel of PCa-associated intact N-glycopeptides (Table 1). 
(F) Network analysis using the list of glycoproteins which carried the differentially abundant intact N-glycopeptides (Table 1). Significant 
enriched KEGG pathway complement and coagulation cascades (FDR < 0.05) and regulation of immune system response (Gene Ontology, 
FDR < 0.05) are colored in blue and red, respectively. 
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N-glycosylation sites covering 256 urinary glycoproteins. 
Thus, this present study clearly represents the deepest 
coverage of the N- and O-glycoproteome of human urine 
to date. 
One of the technical issues associated with 
urine analysis is the high inter- and intra-individual 
variability [6], which was previously shown to account 
for 48% and 66% of CV variation, respectively [48]. In 
addition, the multi-step sample preparation and LC-MS/
MS acquisition are likely sources of technical variation 
[49]. We took advantage of the available TMT labeling 
technology, which not only allowed multiplexing of 
samples to reduce the LC-MS/MS acquisition time, but 
also minimized the technical variation from the sample 
handling [49], especially the peptide enrichment and 
pre-fractionation, while simultaneously facilitating more 
accurate quantification of glycopeptides and non-modified 
peptides [50]. Due to the relative low number of biological 
replicates and high variance between the individuals, 
our study was limited to a non-stringent threshold of 
q < 0.25 for the peptide FDRs to determine differentially 
abundant glycoproteins in PCa and BPH urine. However, 
by validating the levels of specific intact glycopeptides by 
PRM-MS/MS we significantly enhanced the confidence in 
these observations. 
An important limitation of the chosen workflow 
is that, in complex mixtures, co-isolation of multiple 
precursor ions is the most acknowledged limitation 
of quantitative proteomics using isobaric labels. This 
shortcoming reduces the precision and accuracy of the 
quantification [51, 52]. It was demonstrated that due to 
this interference problem, the actual abundance ratios are 
typically underestimated [49]. Using precursor intensity 
fraction (PIF) tool available in MaxQuant [53], we filtered 
peptides that clearly suffer from co-isolation of other 
peptide precursor ions.
Glycans facilitate and contribute to many different 
aspects of tumor progression, including proliferation, 
invasion, angiogenesis and metastasis [54]. In cancer, 
protein glycosylation is dynamically regulated due 
to altered expression of glycan-modifying enzymes 
[55, 56]. Wang et al. [57] showed high expression of 
α1,6-fucosyltransferase (FUT8) in tumor tissue from 
patients with metastatic and aggressive primary PCa and 
was positively correlated with PCa with high Gleason 
scores. The N-glycosylation of proteins was demonstrated 
previously to be altered in urine [58], tissues [21] and 
serum [59] from PCa patients as well as in PCa cell 
lines [20]. Interestingly, using meta-analysis of publicly 
available transcriptomic data from different PCa studies, 
Barfeld et al. [60] reported a concise 33 gene signature 
with biological enrichment for protein glycosylation, 
which discriminates between PCa and BPH across 
multiple transcript detection platforms and sample 
types. Meany et al. [59] reported that direct analysis of 
PSA N-glycosylation in sera may be able to improve the 
sub-optimal specificity of PSA as a PCa marker. Altered 
glycosylation of PSA isolated from PCa serum and/
or seminal plasma relative to PSA glycosylation from 
controls was repeatedly observed by Tabares et al. [61], 
Llop et al. [62] and Ohyama et al. [63]. Collectively, these 
studies clearly support the association of altered of protein 
glycosylation with PCa. Although glycoproteomics studies 
have previously been used to explore PCa [20–22], the 
quantitative information relating to site-specific N- and 
O-glycosylation and the glycan compositions were not 
reported in those studies.
We demonstrated that differentially abundant 
glycopeptides discriminate more accurately between 
PCa and BPH groups than differentially abundant non-
modified peptides. Thus, we argue that a selected panel 
of glycopeptides, but not their corresponding non-
glycosylated peptides from the same protein, may serve as 
candidate biomarkers for PCa detection. We demonstrated 
that the malignant processes associated with PCa are 
more frequently reflected directly in the glycosylation 
of proteins as oppose to the aberrations in the expression 
level or the glycosylation site occupancy of those proteins. 
Although we were limited to investigating a relative small 
patient cohort, the potential of intact glycopeptides to 
stratify patient groups can be explored in follow-up studies 
using larger cohort of patients once the glycoproteomics 
technology matures further allowing more streamlined 
data collection and interpretation of a larger patient cohort.
Among the PCa-associated glycopeptides, we 
targeted the N-glycosylation of prostaglandin-H2 
D-isomerase (PTGDS) and the O-glycosylation of CD59 
using PRM analysis. Interestingly, Davalieva et al. [40] 
and Ahmad et al. [7] showed that these two glycoproteins 
are over-expressed in the urine of PCa patients. Herein, we 
complement their observations by reporting that PTGDS 
and CD59 carry aberrant glycosylation at defined positions 
in PCa urine.
CD59 is a glycosyl-phosphatidylinositol (GPI)-
anchored cell membrane glycoprotein that inhibits 
complement-mediated cell lysis by preventing full 
assembly of the membrane attack complex (MAC) on 
host cells, and thus might confer immune resistance to 
tumor cells [42]. High expression of CD59 protein was 
associated with higher Gleason scores and higher pT stages 
in PCa [41]. It was demonstrated that prostasomes, which 
are secretory granules produced, stored, and released by 
the glandular epithelial cells of the prostate, had higher 
expression of CD59 than those of normal cells [64]. CD59 
glycosylation was previously characterized and several 
roles for the glycans, including spacing and orienting 
CD59 on the cell surface and protecting the molecule from 
proteases were proposed based on structural data [65].
Prostaglandin-H2 D-isomerase was identified in 
human seminal plasma [66]. Prostaglandin D2 (PGD2) 
and prostaglandin D2 synthase (PTGDS) is involved 
in the regulation of testis tissue differentiation [67, 68]. 
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PGD2, which is synthesized by PTGDS in many organs, 
has been implicated as a signaling molecule in the 
mediation or regulation of various biological processes, 
including tumorigenic process in PCa [69]. It was shown 
that PTGDS activity is defined by post-translational 
modifications, and point mutation in a glycosylation site 
(Asn51) inhibited L-PGDS-induced apoptosis and caspase 
3 activity [70]. Interestingly, we identified a significant 
lower abundance in the Asn51 glycoform HexNAc(4)
Hex(5)Fuc(1)NeuAc(2) and HexNAc(5)Hex(6)Fuc(2) in 
PCa compared to BPH urine (Table 1).
The quantitative analysis of intact glycoproteins 
opens novel avenues for assessing the dysregulation 
of glycoproteins in PCa and tie such information with 
aberrant glycoprotein function as drivers or passive by-
products of tumour development and progression.
The quantification of specific peptides glycoforms is 
challenging due to the low ionization efficiency of glycan-
modified peptides, as well as the lack of glycopeptides 
reference spectra. Moreover, multiple glycoforms (micro-
heterogeneity) are detected as separate glycopeptides, thus 
diminishing the signal intensity for each glycopeptide 
form. Selected reaction monitoring (SRM) and parallel 
reaction monitoring (PRM) are currently the leading 
methods for targeted MS-based quantification of proteins. 
Recently, SRM was applied to quantify candidate non-
modified peptides biomarkers in expressed prostatic 
secretions (EPSs) from PCa and control patients [71]. Song 
et al. [72] applied MRM to quantify intact glycopeptides 
in depleted human blood serum using the glycans oxonium 
ions as transitions. However, to this date quantification of 
intact glycopeptides using targeted MS approaches is still 
poorly explored. We showed PRM is a useful approach 
to quantify intact glycopeptides. The number of MS/MS 
spectra recorder increased beyond a 20 fold by using PRM 
for targeted glycopeptide analysis, improving the accuracy 
of the identification and quantitation. Integrating this 
approach with synthetic glycopeptides for normalization 
and absolute quantification would enhance value and 
utility of the PRM-MS/MS workflow even further.
We found the complement and coagulation cascades 
to be over-represented pathways in the set of urinary 
glycoproteins carrying differentially abundant site-
specific glycoforms. Interestingly, the same pathway was 
observed to be enriched in the meta-analysis from Barfeld 
et al. [60] which contained differentially expressed genes 
between localized PCa and benign prostate tissue, thus 
demonstrating that biological processes occurring in 
prostatic tissues may be reflected in urine.
Different coagulation disorders were reported 
during prostatic carcinoma evolution [73]. The most 
frequent coagulation complication is the disseminated 
intravascular coagulation (DIC), which is a result of the 
release of pro-coagulant substances, such as tissue factors, 
into the bloodstream [74]. This coagulation disorder 
was reported in many patients with PCa [75–77]. We 
identified seven glycoproteins displaying aberrant site-
specific glycosylation that are related to complement and 
coagulation cascade pathway. The set of differentially 
abundant site-specific glycoforms belonging to these 
glycoproteins can be explored as candidate biomarkers 
for coagulation disorders that may be present during PCa 
progression.
Additionally, recent reports suggest that the 
complement elements can promote tumor growth in the 
context of chronic inflammation, immunosuppression, 
angiogenesis, and cancer cell signaling [78–80]. Manning 
et al. also showed that human PSA, via its chymotrypsin-
like serine protease activity, can modulate the complement 
system through degradation of iC3b to produce new 
C3 degradation fragments and through degradation of 
the complement protein C5, thereby inactivating the 
complement cascade [81].
In summary, this study reports several innovative 
approaches advancing our pursuit of reliable and sensitive 
urinary biomarker for PCa discovery and stratification 
from BPH by 1) providing the largest coverage of the 
urinary N- and O-glycoproteome to date, 2) providing 
a panel of 56 N-glycopeptides derived from aberrantly 
expressed glycoproteins in PCa urine representing an 
exciting collection of potential candidate biomarkers for 
discrimination of PCa from BHP and by 3) achieving 
confident structural characterization including the peptide 
carrier identity, site annotation, and glycan composition as 
well as quantitative validation of the panel of glycopeptide 
candidate markers by the application of innovative LC-
MS/MS and PRM approaches of intact glycopetides. This 
study opens new promising avenues for using urinary 
glycoproteins, a hitherto largely untapped resource, as 
candidate biomarkers for PCa detection.
MATERIALS AND METHODS
Urine collection, protein extraction and peptide 
generation
The study was approved by the ethics review 
board of the Instituto do Câncer do Estado de São Paulo 
(ICESP), under the protocol nº784/15. Written informed 
consents were obtained from all participants. The 
methods were performed in accordance with the approved 
guidelines and regulations. 
The first voided urine after prostate biopsy was 
collected prospectively from men who were admitted for 
prostate biopsies based on serum PSA levels ≥ 4.0 ng/ml 
and/or abnormal DRE. All men had received study 
information, and they had signed the informed consent. In 
this study, a total of 12 subjects were included, of whom 6 
were validated to have PCa based on biopsy examination 
by a trained pathologist. The men were asked to void, and 
the first ~30 ml of urine was collected and immediately 
cooled on ice. The samples were centrifuged at 3,000 × g 
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for 10 min at 4° C. The cleared supernatant (~2–20 ml) 
was further filtered using 0.22 μm filters (Millipore, 
Billerica, MA). Two milliliters of filtered urine was 
then concentrated using 10 kDa cutoff filters (Millipore, 
Billerica, MA) and stored immediately at −20° C until 
further use. The total protein amount was determined 
using Qbit fluorometric quantitation (Thermo). 
Protein digestion and desalting
Proteins (100 µg) were reduced by addition of 
dithiothreitol (DTT) to a final concentration of 10 mM and 
incubated for 30 min at 30° C. Proteins were alkylated 
prior to digestion by the addition of iodoacetamide 
(IAA) to a final concentration of 40 mM and incubated 
for 30 min in the dark at room temperature. To quench 
the reaction, DTT was added to a final concentration 
of 10 mM. Porcine trypsin (1:50, w/w, sequence-grade, 
Promega) was added, and the mixture incubated overnight 
at 37° C. The reaction was stopped with the addition of 
1% TFA and the resulting peptides were purified using a 
primed Oligo R3 reversed phase SPE micro-column and 
dried [29].
Isobaric peptide labeling with TMT
Peptides originating from ~100 µg protein from each 
urine sample were dissolved in 100 µl 100 mM TEAB 
and labeled individually with TMT-10plex mass tags 
(Thermo) according to the manufacturer’s instructions. 
Briefly, each TMT10plex tag (0.8 mg) was resuspended 
with 41 μl neat anhydrous acetonitrile and added to each 
of the peptide samples and the mixture incubated for 1 h 
at room temperature after vigorous vortexing for 5 min. 
To quench the reaction, 8 μl 5% (v/v) hydroxylamine was 
added per sample followed by 15 min incubation at room 
temperature. After TMT labelling, all peptide samples 
were mixed 1:1 (w:w), divided into two aliquots (~500 µg 
each) and purified on a primed Oligo R3 reversed phase 
SPE micro-column.
Glycopeptide enrichment using titanium dioxide 
(TiO2) SPE
One of the aliquots from the TMT-labeled peptide 
samples (~500 µg) was used for sialoglycopeptide 
enrichment using TiO2 SPE according to Larsen et al. [28] 
and Palmisano et al. [29]. Samples were resuspended in 
1 ml loading buffer containing 1 M glycolic acid, 80% 
acetonitrile (ACN), 5% TFA. The samples were incubated 
with TiO2 beads (GL Sciences, Japan, 5 µm) using a total 
of 0.6 mg TiO2 beads per 100 µg peptides and shaken 
at room temperature for 15 min. The suspension was 
centrifuged at 1,000 × g for 1 min and the supernatant 
transferred to another vial with a fresh batch of TiO2 
beads (containing half the amount of TiO2 beads as 
initially used) and shaken at room temperature for 15 min. 
The two batches of TiO2 beads were washed with 
100 µl loading buffer and centrifuged at 1,000 × g for 1 min. 
The supernatant was discarded and the beads washed with 
100 µl washing buffer 1 containing 80% ACN in 1% 
aqueous TFA (both v/v) and centrifuged at 1,000 × g for 
1 min. The supernatant was discarded and the beads were 
washed with 100 µl washing buffer 2 containing 20% 
ACN in 0.2% aqueous TFA (both v/v) and centrifuged at 
1,000 × g for 1 min. The supernatant was again discarded 
and the beads were dried in a vacuum centrifuge for 
5 min. The bound peptides were eluted by resuspending 
the TiO2 beads in 100 µl elution buffer containing 1% (v/v) 
aqueous ammonium hydroxide and by vortexing the beads 
for 15 min. The mixtures were then centrifuged at 1,000 × g 
for 1 min, the peptide-containing supernatant transferred 
to separate tubes and the eluted peptides were aliquoted 
and dried by vacuum centrifugation. This produced an 
enriched sialoglycopeptide fraction. 
Glycopeptide enrichment using hydrophilic 
interaction liquid chromatography (HILIC) SPE
The second aliquot of TMT-labeled urinary peptides 
(~500 µg) was reconstituted in 100 µl loading and washing 
buffer containing 80% ACN in 1% aqueous (both v/v) 
TFA. Peptides were loaded onto a primed custom-made 
HILIC SPE micro-column according to Mysling et al. [30] 
packed with PolyHYDROXYETHYL A™ resin (PolyLC 
Inc) onto a supporting C8 disk (Empore) in a p200 pipette 
tip. The flow-through fraction was collected. The HILIC 
SPE columns were then washed in 100 µl loading and 
washing buffer and the wash fraction was collected and 
combined with the first flow-through fraction for separate 
downstream analysis. The enriched glycopeptides were 
eluted with 50 μl 0.1% (v/v) TFA followed by 50 μl 
25 mM NH4HCO3 and finally 50 μl 50% (v/v) ACN; these 
three elute fractions were combined. The flow through 
and the combined elute fraction were dried by vacuum 
centrifugation and purified on a primed Oligo R3 reversed 
phase SPE micro-column, aliquoted and dried again 
by vacuum centrifugation. This produced an enriched 
glycopeptide fraction.
PNGase F and sialidase treatment
An aliquot of the TiO2 or HILIC SPE enriched 
(sialo)glycopeptides was resuspended in 50 mM TEAB, 
pH 8.0 and simultaneously de-N-glycosylated using 500 U 
N-glycosidase F (PNGase F) (New England Biolabs, 
Ipswich, MA) and de-O-sialylated using 0.1 U broad-
specificity sialidase A (Prozyme Hayward, CA). The 
PNGase F and sialidase treatment were carried out 
concomitantly for 12 h at 37° C with the purpose of 
achieving efficient de-N-glycosylation while rendering 
the O-glycopeptide more amendable to LC-MS/MS 
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characterization. After incubation, the de-N-glycosylated 
and de-O-sialylated peptides were purified on a primed 
Oligo R3 reversed phase SPE micro-column, dried by 
vacuum centrifugation and reconstituted in 50 µl 0.1% 
formic acid prior to LC-MS/MS analysis.
HILIC HPLC pre-fractionation
The desialylated glycopeptides enriched by TiO2 as 
well as the flow through containing asialoglycopeptides 
were resuspended in 90% ACN in 0.1% (both v/v) aqueous 
TFA and injected onto an HPLC column (320 μm ID × 
170 mm length) packed in-house using TSKgel Amide-80 
HILIC 5 μm resin (Tosoh Bioscience) connected to an 
Agilent 1200 micro-HPLC instrument. Briefly, samples 
were suspended in solvent B containing 90% ACN in 
0.1% (both v/v) aqueous TFA. Peptides were loaded onto a 
320 μm peak HILIC LC column and eluted at 6 μl/min by 
decreasing the solvent B from 100–60% over 42 min [82]. 
Fractions were automatically collected in a 96 well plate 
at 1 min intervals after UV detection at 210 nm and dried 
by vacuum centrifugation, combined in 8–16 relevant 
fractions according to the corresponding UV profile and 
stored at −20° C until LC–MS/MS analysis.
Mass spectrometry analysis
The pre-fractionated peptides were resuspended 
in 0.1% FA and automatically loaded on a trap column 
(2 cm × 100 µm inner diameter) custom packed 
with ReproSil-Pur C18 AQ 5 µm resin (Dr. Maisch, 
Ammerbuch-Entringen, Germany). A total of ~1 µg of 
peptide was injected. The peptides were separated at 250 
nl/min on an analytical column (17 cm × 75 µm) packed 
with 3 µm resin of the same kind operated in reversed 
phase chromatography mode using an EASY-nanoLC 
system (Thermo Fisher Scientific, Odense, Denmark). The 
mobile phases were 95% ACN in 0.1% (both v/v) aqueous 
FA (solvent B) and aqueous 0.1% (v/v) FA (solvent A). 
The linear gradient of solvent A increased from 3% to 
28% over 52 min, 28–47% over 5 min, 45–100% over 5 
min and 8 min at 100% B. The nanoLC was connected 
to a Q Exactive HF Hybrid Quadrupole-Orbitrap mass 
spectrometer (Thermo Fisher Scientific) operating in 
positive ion mode and using data dependent acquisition. 
The Orbitrap acquired the full MS scan with an automatic 
gain control (AGC) target value of 3 × 106 ions and a 
maximum fill time of 100 ms. Each MS scan was acquired 
at high-resolution 120,000 full width half maximum 
(FWHM) at m/z 200 in the Orbitrap with a m/z range 
of 400–1600 Da. The 10 most abundant precursor ions 
were selected from each MS full scan for higher-energy 
collision-induced dissociation (HCD) fragmentation using 
normalized collision energy (NCE) of 29% if they were 
at least doubly charged. Fragmentation was performed 
at high resolution (60,000 FWHM) for a target of 
1 × 105 product ions and a maximum injection time of 
200 ms using a precursor isolation window of m/z 1.2 and 
a dynamic exclusion of 30 s after a single isolation and 
fragmentation of a given precursor. 
For parallel reaction monitoring (PRM), full MS 
scans were acquired at 60,000, AGC target was 1 × 106, 
maximum injection time was 100 ms and the m/z range 
was 700–1800. HCD fragmentation was performed using 
an inclusion list with the following parameters: 60,000 
resolution for an ion target of 1 × 105 and a maximum 
injection time of 150 ms using an isolation window of m/z 
1.6 and a fixed lower m/z of 110.
Analysis of intact N-glycopeptides 
Intact glycopeptide HCD-MS/MS fragment spectra 
from each sample were searched against defined protein 
and glycan search spaces using the Byonic software 
v2.6.46 (Protein Metrics, https://www.proteinmetrics.
com/) [83]. Searches were performed with the following 
fixed modifications: precursor ion mass tolerance 
of 10 ppm, product ion mass tolerance of 0.02 Da, 
carbamidomethylation of Cys, and strict trypsin specific 
cleavage with a maximum of two missed cleavages per 
peptide. Searches were also conducted with the following 
variable modifications: oxidation of Met (+15.994 Da), 
TMT (+229.163) at N-term and K, and N-glycosylation 
of sequon-localized Asn with the predefined N-glycan 
database of 309 mammalian N-glycans without sodium 
or O-glycosylation of Thr and Ser with the predefined 
O-glycan database containing 78 common mammalian 
O-glycans without sodium available within Byonic. 
To narrow the protein search space only the list of 
glycoproteins identified by the detection of sequon-
containing de-N-glycosylated peptides generated by 
PNGase F treatment were used in the protein database 
for the identification of intact N-glycopeptides. For intact 
O-glycopeptides, a protein database was composed by 
glycoproteins annotated in UniProtKB. All searches were 
filtered to <1% false discovery rate (FDR) at the protein 
level and 0% at the peptide level by using a decoy database 
of the reversed sequences of the list of proteins used for the 
original (forward) protein search space [84]. We conducted 
strict filtering criteria, where only glycopeptides identified 
with high score ID was considered (PEP 2D scores 
< 0.001). PEP 2D scores less than 0.001 means that 
there is less than 0.1% chance of having an incorrectly 
annotated peptide (but not necessarily correct annotation 
of the site and glycan composition) of the glycopeptides 
[27]. Further manual validation was performed for 
glycopeptides with “difficult-to-assign” glyco-features 
e.g. NeuGc-containing glycopeptides were validated by 
searching for the diagnostic ions pertaining to NeuGc 
m/z 308.090/290.090 at a mass tolerance of 10 ppm [85]. 
Using oxonium ions to validate glycopeptides should be 
performed carefully since co-isolation of different intact 
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glycopeptides within the same m/z isolation window 
occurs especially in complex peptide samples. This 
was observed for some intact N-glycopeptides, which 
were tentatively assigned as non-NeuAc containing 
glycopeptides, but with a clear presence of m/z 274/292 
oxonium ions in the corresponding HCD-MS/MS spectra, 
useful diagnostic ions for NeuAc-containing glycopeptides 
(Supplementary Figure 7).
Protein identification and glycosylation site 
analysis
For protein identification and glycosylation site 
analysis, LC-MS/MS raw files were imported into 
MaxQuant version 1.5.2.8 [53]. The database search 
engine Andromeda [86] was used to search the HCD- and 
CID-MS/MS spectra against a database composed of the 
reviewed UniProtKB human protein database (release 
April 15, 2015; 45,185 entries) with a precursor ion 
tolerance level of 4.5 ppm and product ion mass accuracy 
thresholds of 20 ppm and 0.5 Da for HCD-MS/MS and 
CID-MS/MS, respectively. For the reporter fragment ions, 
the 10-plex TMT was included in the search parameters 
and enzyme specificity was set to trypsin with a maximum 
of two missed cleavages. Carbamidomethylation of 
Cys (+57.021 Da) was set as a fixed modification, and 
oxidation of Met (+15.994 Da), deamidation of Asn 
and Gln (+0.984 Da) and protein N-terminal acetylation 
(+42.010 Da) were selected as variable modifications. 
Five variable modifications per peptide were allowed. 
All identifications were filtered in order to achieve 
1% PSM and Protein FDR. The reporter ion intensities 
for each PSM with PIF (precursor ion fraction) > 0.75 
were calculated using MaxQuant. The quantitation of 
the identified proteins was determined by reporter ion 
intensities using at least 1 razor/unique peptide.
After excluding peptides identified as potential 
contaminants or appearing in the reverse database, we 
manually filtered the peptides containing the deamidation 
sites located within the conserved N-glycosylation motif 
i.e. NxS/T/C where x ≠ P. 
Bioinformatic analysis 
Bioinformatic analyses were performed using 
Perseus v.1.5.4.1 which is available within MaxQuant. 
The reporter ion intensities from redundant peptides 
were summed. The quantitation of the identified de-N-
glycopeptides and non-modified peptides was performed 
by normalizing the reporter ion intensities by log2 
conversion and subtracting them by the log2 mean of each 
sample. The first biological replicate of the BPH sample 
did not cluster together with the rest of the samples as 
assessed by principal component analysis (PCA) and 
was therefore removed. Statistical tests were carried 
out using the Limma R package [36], which have been 
shown to perform well for proteomics data in the case of 
low replicate numbers and missing values [87]. Resulting 
p-values were corrected for multiple statistical testing and 
converted into false discovery rates of q < 0.25.
PCA was constructed in the web-based 
chemometrics platform MetaboAnalyst version 2.0 [88]. 
Protein-protein interaction networks and enrichment 
analyses were performed using the STRING software [89].
Lectin blotting analysis
An aliquot of 20 μg urinary proteins were separated 
by discontinuous electrophoresis (stacking gel consisting 
of 4% polyacrylamide and resolving gel consisting of 12% 
polyacrylamide) for 1 h. The separated proteins were then 
transferred to a polyvinylidene fluoride (PVDF) membrane 
by wet electroblotting using the Tris/glycine transfer 
buffer overnight at 4°C. PVDF membranes were blocked 
in TBS-T and 5% BSA at room temperature for 1 h. The 
membranes were incubated with the following lectins 
(all from Vector Laboratories, Burlingame, CA, USA) in 
TBST for 16 h at a dilution of 1:2000 (v:v) concanavalin 
A (Con A), Maackia amurensis lectin (MAL), wheat germ 
agglutinin (WGA), Aleuria aurantia lectin (AAL) and 
Ricinus communis agglutinin (RCA).
Then membranes were washed three times for 5 
min each with TBS-T and incubated with streptavidin-
HRP conjugate (Vector Laboratories, Burlingame, CA, 
USA, 1:5,000 for Con A and 1:2,000 for AAL, MAL, 
WGA and RCA) at room temperature for 1 h followed 
by three washes with TBS-T. The PVDF membranes 
were analyzed with Western Blotting Analysis System 
Bio-Rad Image Lab™ Software (BIO-RAD). The 
subsequent densitometry analysis of the resulting bands 
was performed with the Image J Software or Image Lab. 
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